Drugs / DTaP-IPV//PRP~T
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00315055 Comparator | Jul 2006 → Jul 2007 | diphtheria, hepatitis B virus infection, pertussis, poliomyelitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTaP-IPV//PRP~T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00315055 ↗ |
| Modality | Vaccine | “Participants will receive 3 vaccinations with DTaP-IPV-PRP\~T (PENTAXIM™ ) and recombinant Hepatitis B (ENGERIX® PEDIATRIC) vaccines.” NCT00315055 ↗ |
| Route | Intramuscular | “0.5 mL, IM” NCT00315055 ↗ |